Oricchio, Elisa2024-07-032024-07-032024-07-032024-05-3110.1038/s41589-024-01631-3https://infoscience.epfl.ch/handle/20.500.14299/208994WOS:001239210600001We developed a rational approach to design peptide-based covalent inhibitors and coupled the inhibitors with antibodies for cell-specific delivery. We used this platform to generate antibody-peptide inhibitor conjugates (APICs) that target a family of proteases, the cysteine cathepsins. Our drug design and targeted delivery approach ensure specific inhibition and achieve therapeutic efficacy in different cancer cells and osteoclasts.Life Sciences & Biomedicinetext::journal::journal article::research article